I hope you guys enjoy this new series I am doing. It is called Batman You Forgot About. I talk about villains or things that ...

Sitting on the shoulders of the man she calls Dad, Tiger Lily Hutchence was clearly having the time of her young life as she giggled her way through her fifth birthday. Tiger, dressed in a pink ...

Eli Lilly has seen tremendous growth from its new GLP-1 drugs, which people have been using for weight loss. Sales growth should continue as the company increases production and looks to win ...

While Eli Lilly missed on both the top and bottom lines in its Q3 financial results, a look at its sales figures -- and especially sales growth -- would make many other pharmaceutical companies ...

Chinese biotech Laekna Therapeutics on Wednesday announced a clinical collaboration with Eli Lilly (NYSE:LLY) to develop an obesity therapy that can avoid loss of muscle mass, a problem often ...

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the focus of its oral IL-17 psoriasis program to a follow-up molecule. Lilly kicked DC ...

SITTING on the shoulders of the man she calls Dad, Tiger Lily Hutchence was clearly having the time of her young life as she giggled her way through her fifth birthday. Tiger, dressed in a pink ...

Of Lilly’s $3.11 billion in quarterly sales from Mounjaro, $2.4 billion came from the U.S. Related Compounders sue FDA for removing Eli Lilly's tirzepatide from shortage list ...

AJ Mast / Bloomberg via Getty Images Eli Lilly (LLY) shares tumbled 12% at the opening bell Wednesday after its third-quarter results fell well short of analysts' estimates and it lowered its full ...

Shares of Eli Lilly (NYSE: LLY) were sinking 6.3% lower as of 11:11 a.m. ET on Wednesday. The sharp decline came after the big drugmaker announced its third-quarter results before the market opened.

Eli Lilly lost the momentum it had during the first half of the year. However, the company still has plenty of long-term growth drivers. The pharmaceutical giant's prospects justify its current ...